Livestock Vaccine MarketSize, Share & Industry Analysis, 2026-2034By Animal TypeBy Vaccine TypeBy Disease/indicationBy Route of AdministrationBy Distribution Channel

Livestock vaccines are biological products administered to farm animals, including poultry, swine, cattle, sheep, goats and farmed aquatic species, to prevent or control infectious and parasitic diseases before they spread through a herd or flock. They are formulated as live attenuated, inactivated, toxoid, subunit or vector-based products and delivered by injection, oral dosing, spray or in-ovo application depending on the species and disease targeted. Buyers span integrated poultry and swine producers, individual cattle and small ruminant farmers, aquaculture operators, veterinary practices and government animal health agencies running compulsory disease-control programs.

Growth of 6.93% a year carries the global livestock vaccine market from USD 6.85 billion in 2025 to USD 12.48 billion in 2034. The full series behind that rate covers USD 5.05 billion in 2020, USD 6.43 billion in 2024, USD 7.3 billion in 2026 and USD 9.51 billion in 2030, with 2025 as the base year.

Composition changes more than the total does. Aquaculture, at 11.06%, outgrows Swine at 6.36%, and its share moves from 7.01% to 10.02%. Poultry stays the largest line throughout, at USD 2.33 billion in 2025 and USD 4.12 billion in 2034. The lines gaining share are Aquaculture and Other Livestock (Equine & Others). Poultry, Swine, Cattle (Bovine) and Sheep & Goat (Ovine/Caprine) lose share without losing revenue.

By vaccine type, Live Attenuated accounts for 37.96% of 2025 revenue at USD 2.6 billion, reaching USD 4.24 billion and 34% by 2034. DNA & Vector-based grows faster at 11.81% against 5.58%, moving from 5.99% of revenue to 8.98% by 2034. This axis divides the same revenue as the animal type split instead of adding to it, so the two are read together and never summed.

The regional order runs from Asia Pacific at 32% of 2025 revenue down to Middle East and Africa at 7%. Asia Pacific is worth USD 2.19 billion in 2025 and USD 4.37 billion in 2034; North America, second at 24%, moves from USD 1.64 billion to USD 2.62 billion. Because Asia Pacific, Latin America and Middle East and Africa take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

Coverage extends to five regions, six animal type lines and five segmentation axes over the full fifteen years. The 2025 total itself is triangulated from published sources and category proxies, with no independently sourced count behind it, and the splits below are estimated on that same basis, a bound on their precision worth carrying into any use of them.

• The global livestock vaccine market moves from USD 5.05 billion in 2020 to USD 6.85 billion in 2025 and USD 12.48 billion by 2034, the forecast period compounding at 6.93% a year.
• 34.01% of 2025 revenue sits in Poultry (USD 2.33 billion) and it remains the largest animal type line in 2034 at USD 4.12 billion and 33.01%.
• Aquaculture is the fastest-growing line at 11.06%, lifting its share from 7.01% in 2025 to 10.02% in 2034 and its revenue from USD 0.48 billion to USD 1.25 billion.
• Scenario range for 2034 runs from USD 11.48 billion in the bear case to USD 13.48 billion in the bull case, against a base-case USD 12.48 billion, the spread a plan built on this forecast has to absorb.
• Asia Pacific holds 32% of global revenue in 2025 at USD 2.19 billion, the largest of the five regions tracked, and reaches USD 4.37 billion by 2034.
• 34% of Asia Pacific's base-year revenue comes from China alone: USD 0.74 billion in 2025, rising to USD 1.49 billion by 2034, which is why it is that region's worked example.
• Every line on all five segmentation axes and in each of the five regions carries its own revenue, share and growth rate for all fifteen years, 2020 through 2034, on a 2025 base.

Read across the forecast period, the global livestock vaccine market shows movement in three places: animal type composition, regional weight, and the 6.93% rate applied to the whole.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

The animal type mix tilts toward Aquaculture. 11.06% against 6.36%: that gap, between Aquaculture and Swine, is the largest on the animal type axis. Shares follow: 7.01% to 10.02% for Aquaculture, 22.04% to 20.99% for Swine. In absolute terms Aquaculture rises from USD 0.48 billion to USD 1.25 billion, while Swine rises from USD 1.51 billion to USD 2.62 billion. Both grow; the gap is wide enough to reshape the mix inside a single forecast window.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 32% of revenue in 2025 to 35% in 2034, worth USD 2.19 billion rising to USD 4.37 billion; Latin America moves from 15% of revenue in 2025 to 17% in 2034, worth USD 1.03 billion rising to USD 2.12 billion; Middle East and Africa moves from 7% of revenue in 2025 to 8% in 2034, worth USD 0.48 billion rising to USD 1 billion. Against that, North America at 24% moving to 21%, Europe at 22% moving to 19%, a fall in share, not in revenue. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.

Growth compounds at 6.93% without a step change. Reading the series: USD 5.05 billion in 2020, USD 6.43 billion in 2024, USD 6.85 billion in 2025, USD 7.3 billion in 2026, USD 9.51 billion in 2030 and USD 12.48 billion in 2034. The forecast rate of 6.93% sits against 6.29% over the historical period, so the projection extends an observed trend instead of proposing a new one. For a participant that makes planning a question of capturing a share of steady expansion instead of timing a discontinuity, and it is why the animal type and regional mixes matter more to a forecast than the headline rate does.

Aquaculture adds the most incremental growth

Growth in the global livestock vaccine market comes from three measurable sources over 2026-2034: the market's own compounding at 6.93%, the share gained by faster-growing animal type lines, and expansion in the regions taking a larger part of global revenue.

The bear case and what drives it

Where the forecast could be beaten

Revenue is concentrated in Poultry

USD 1.64 billion of 2025 revenue is generated in North America, 24% of the global livestock vaccine market with USD 2.62 billion projected for 2034. It is a leading region on this axis, second by revenue throughout the period.

By 2034 the share stands at 21%, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Within the region the animal type split tracks the global one; 34.01% of 2025 revenue in Poultry, fastest growth of 11.06% in Aquaculture. The full report breaks North America out along every axis and by country.

85% of North America's base-year revenue comes from the United States; USD 1.39 billion, rising to USD 2.23 billion by 2034. Because it is 85% of the region in the base year, North America's totals move with this one country instead of a spread of them. The region itself runs USD 1.64 billion to USD 2.62 billion over the same period, and this is the market carrying the country-level detail in the full report.

Composition here matches the global split: the largest line is Poultry at 34.01% of 2025 revenue, easing to 33.01% by 2034, and the fastest is Aquaculture at 11.06%, from 7.01% to 10.02%. With 85% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Per-animal type revenue for the United States appears on its own in the full report.

Livestock vaccines in the United States fall under the Center for Veterinary Biologics at the Animal and Plant Health Inspection Service, part of the Department of Agriculture, a distinct track from the drug approvals the Food and Drug Administration handles. A manufacturer must hold an establishment licence and a product licence before any vaccine reaches the market, with each production batch subject to serial release testing for purity, safety and potency. Labelling must state the target species, indications, storage conditions and an expiry date, and any claim of efficacy must be backed by data submitted to the agency. Facilities are inspected on a recurring basis to confirm that production stays within the conditions under which the licence was granted. Combination and autogenous vaccines follow their own supplementary review paths within the same framework.

Supplier positions in the United States sit on the animal type axis: the country buys the same lines the global market does, in the same order. The commercially relevant division is 34.01% of 2025 revenue in Poultry, where the volume is, against 11.06% growth in Aquaculture, where share moves. Country-level shares and positioning per company sit in the full report.

Within North America, Canada accounts for 15% of regional revenue and 3.65% of the global total, worth USD 0.25 billion in 2025 and USD 0.39 billion by 2034.

In Europe, 22% of global revenue puts 2025 at USD 1.51 billion and reaches USD 2.37 billion by 2034. Among the five regions it ranks third by revenue in both years.

Share settles at 19% in 2034, though revenue still rises throughout; the shift is in the region's weight against faster-growing ones, which is not the same as weakening demand.

Poultry leads here as it does globally, at 34.01% of 2025 revenue, and Aquaculture again grows fastest at 11.06%. Europe is reported axis by axis and country by country in the full study.

28% of Europe's base-year revenue comes from Germany; USD 0.42 billion, rising to USD 0.66 billion by 2034. Its 28% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Regional revenue of USD 1.51 billion in 2025 and USD 2.37 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in Germany follows the animal type mix reported at global level: Poultry is the largest line at 34.01% of 2025 revenue, moving to 33.01% by 2034, while Aquaculture grows fastest at 11.06% and takes its share from 7.01% to 10.02%. Its 28% weight in Europe means those movements carry straight into the regional totals. Per-animal type revenue for Germany appears on its own in the full report.

As a member state, Germany applies the European Union's veterinary medicines framework, with the Paul-Ehrlich-Institut acting as the national authority for immunological veterinary products alongside the European Medicines Agency for centrally authorised vaccines. A supplier must secure a marketing authorisation demonstrating quality, safety and efficacy before a livestock vaccine can be sold, and manufacturing sites must operate under Good Manufacturing Practice certified through routine inspection. Labelling and the accompanying package leaflet must identify the target species, withdrawal periods where relevant, storage instructions and batch identification. Pharmacovigilance obligations continue after authorisation, requiring the holder to report adverse events. Cross-border recognition within the bloc lets a product authorised elsewhere in the Union enter the German market through mutual recognition rather than a fully separate national review.

What separates suppliers in Germany is where they sit on the animal type axis, not which country they serve. Poultry, at 34.01% of 2025 revenue, is where the volume sits, and Aquaculture, growing at 11.06%, is where position changes hands over the forecast period. A supplier weighted toward Europe is competing over a base of USD 1.51 billion in 2025 reaching USD 2.37 billion by 2034, 22% of global revenue at the start of that period.

Within Europe, France accounts for 22% of regional revenue and 4.82% of the global total, worth USD 0.33 billion in 2025 and USD 0.52 billion by 2034.

Within Europe, the United Kingdom accounts for 18% of regional revenue and 3.94% of the global total, worth USD 0.27 billion in 2025 and USD 0.43 billion by 2034.

USD 2.19 billion of 2025 revenue is generated in Asia Pacific, 32% of the global livestock vaccine market and reaches USD 4.37 billion by 2034. That makes it the first-largest region covered, in 2025 and again in 2034.

Share climbs to 35% by 2034, because it outgrows the market's 6.93%; the revenue added here is disproportionate to where the region started.

Within the region the animal type split tracks the global one; 34.01% of 2025 revenue in Poultry, fastest growth of 11.06% in Aquaculture. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

China is the largest market within Asia Pacific, generating USD 0.74 billion in 2025 and projected to reach USD 1.49 billion by 2034. Its 34% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. Regional revenue of USD 2.19 billion in 2025 and USD 4.37 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in China follows the animal type mix reported at global level: Poultry is the largest line at 34.01% of 2025 revenue, moving to 33.01% by 2034, while Aquaculture grows fastest at 11.06% and takes its share from 7.01% to 10.02%. Its 34% weight in Asia Pacific means those movements carry straight into the regional totals. China carries its own animal type breakdown in the full report.

China regulates livestock vaccines through the Ministry of Agriculture and Rural Affairs, with the China Institute of Veterinary Drug Control responsible for batch testing and technical review ahead of market entry. A supplier must obtain a veterinary biologics production licence and register each product before distribution, and every batch destined for sale is subject to mandatory lot release testing conducted by the institute rather than left to manufacturer self-certification. Labelling must be in Chinese and state the strain composition, target species, dosage and storage requirements. Domestic manufacturing facilities are inspected against national Good Manufacturing Practice standards, and imported vaccines face additional registration steps specific to foreign-produced biologics. State procurement programmes for certain epidemic-control vaccines run alongside the standard commercial approval route.

Competition in China is decided on the animal type axis rather than on geography, since suppliers here sell into the same animal type lines reported globally. Volume sits in Poultry at 34.01% of 2025 revenue; movement sits in Aquaculture at 11.06% growth. The commercial size of that position is USD 2.19 billion in 2025, moving to USD 4.37 billion by 2034 across the forecast period.

7.01% of global revenue is generated in India; USD 0.48 billion in 2025, reaching USD 0.96 billion in 2034, and 22% of Asia Pacific.

Japan is sized at USD 0.26 billion in 2025, rising to USD 0.52 billion by 2034; 3.8% of global revenue and 12% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

15% of the global livestock vaccine market sits in Latin America in 2025, worth USD 1.03 billion and reaches USD 2.12 billion by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

Its share rises to 17% over the forecast period, because it outgrows the market's 6.93%; the revenue added here is disproportionate to where the region started.

Within the region the animal type split tracks the global one; 34.01% of 2025 revenue in Poultry, fastest growth of 11.06% in Aquaculture. Latin America is reported axis by axis and country by country in the full study.

Brazil is the largest market within Latin America, generating USD 0.57 billion in 2025 and projected to reach USD 1.17 billion by 2034. 55% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 1.03 billion in 2025 and USD 2.12 billion in 2034, it is the country the full report breaks out in detail.

The animal type pattern in Brazil is the global one: 34.01% of 2025 revenue in Poultry, 33.01% by 2034, against 11.06% growth in Aquaculture taking it from 7.01% to 10.02%. Since 55% of Latin America's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. Per-animal type revenue for Brazil appears on its own in the full report.

The Ministry of Agriculture and Livestock, through its Department of Animal Health, governs the registration and oversight of livestock vaccines in Brazil. A supplier must register each product before sale, submitting data on composition, safety and efficacy specific to the target species and the disease it addresses. Manufacturing establishments require their own operating licence and are inspected against Good Manufacturing Practice standards particular to veterinary biologics. Labelling must appear in Portuguese and disclose the antigen composition, batch number, target species, storage conditions and any withdrawal period. Official batch release testing applies to certain vaccine categories before distribution is permitted. Import of foreign-manufactured vaccines follows a parallel registration route that still requires evidence generated under Brazilian conditions where the disease profile warrants it.

What separates suppliers in Brazil is where they sit on the animal type axis, not which country they serve. The commercially relevant division is 34.01% of 2025 revenue in Poultry, where the volume is, against 11.06% growth in Aquaculture, where share moves. The commercial size of that position is USD 1.03 billion in 2025 and USD 2.12 billion by 2034, 15% of the global total in the base year.

Mexico is sized at USD 0.23 billion in 2025, rising to USD 0.47 billion by 2034; 3.36% of global revenue and 22% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.

Middle East and Africa holds 7% of the global livestock vaccine market in 2025, worth USD 0.48 billion rising to USD 1 billion in 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share has moved up to 8%, so the region grows faster than the market's 6.93% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Poultry leads here as it does globally, at 34.01% of 2025 revenue, and Aquaculture again grows fastest at 11.06%. Middle East and Africa is reported axis by axis and country by country in the full study.

The largest single market in Middle East and Africa is Saudi Arabia, at USD 0.14 billion in 2025 and USD 0.3 billion in 2034. 30% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 0.48 billion in 2025 and USD 1 billion in 2034, it is the country the full report breaks out in detail.

Demand in Saudi Arabia follows the animal type mix reported at global level: Poultry is the largest line at 34.01% of 2025 revenue, moving to 33.01% by 2034, while Aquaculture grows fastest at 11.06% and takes its share from 7.01% to 10.02%. Its 30% weight in Middle East and Africa means those movements carry straight into the regional totals. Per-animal type revenue for Saudi Arabia appears on its own in the full report.

Saudi Arabia regulates livestock vaccines through the Ministry of Environment, Water and Agriculture, working alongside the Saudi Food and Drug Authority on registration and quality oversight of veterinary biologics. A supplier must register a product before it can be marketed, with dossiers reviewed for composition, target species and manufacturing quality, and imported vaccines undergo additional customs and quarantine checks tied to the kingdom's animal health protections. Facilities supplying the market, whether domestic or foreign, must demonstrate conformity with recognised Good Manufacturing Practice standards. Labelling must appear in Arabic, stating the target species, storage conditions, batch identification and expiry information. Vaccines addressing diseases under national eradication or control programmes may face separate approval conditions set directly by the ministry.

Saudi Arabia does not have a competitive structure of its own; position here is position on the animal type axis reported above. Two different problems sit on the same axis: holding Poultry at 34.01% of 2025 revenue, and taking Aquaculture while it grows at 11.06%. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.48 billion in 2025 reaching USD 1 billion by 2034, 7% of global revenue at the start of that period.

1.75% of global revenue is generated in South Africa; USD 0.12 billion in 2025, reaching USD 0.25 billion in 2034, and 25% of Middle East and Africa.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by Animal Type, Vaccine Type, Disease/Indication, Route of Administration, Distribution Channel, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.